FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.038,21 -644,54 (-1,08%)
Supernus Pharmaceuticals, Inc. (SUPN)
Dopo ore:
| Chiusura precedente | 29,31 |
| Aperto | 29,46 |
| Denaro | 30,02 x 100 |
| Lettera | 30,12 x 200 |
| Min-Max giorno | 29,18 - 30,18 |
| Intervallo di 52 settimane | 21,99 - 38,09 |
| Volume | |
| Media Volume | 388.661 |
| Capitalizzazione | 1,646B |
| Beta (5 anni mensile) | 0,99 |
| Rapporto PE (ttm) | 1.503,50 |
| EPS (ttm) | 0,02 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 40,50 |
GlobeNewswireSupernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
ROCKVILLE, Md., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). Working closely with the U.S. Food and Drug Administratio
- GlobeNewswire
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will host and webcast a Research & Development (R&D) Day on Wednesday, October 18, 2023. During the event, members of Supernus’ senior management team will provide an overview of the Company’s pipeline, with emphasis on SPN-820/821, SPN-81
- GlobeNewswire
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with ADHDFinal long-term data show Qelbree consistently improved symptoms and executive function in adults with ADHD, with safety and tolerability similar to the short-term pivotal adult Phase III trial ROCKVILLE, Md., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharma
